SEOUL, South Korea, April 23, 2025 /PRNewswire/ — CGBIO(CEO Hyun Seung Yu), a leading Korean company specializing in bio-regenerative medicine, proudly announces that its innovative bone graft substitute, NOVOSIS PUTTY, has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA). This pivotal approval paves the way for a clinical trial in spinal fusion procedures within the United States.

Researchers at Umeå University, Sweden, have discovered a previously unknown type of connective tissue cells that surround cancer cells in pancreatic tumors. The newly discovered cells counteract tumor development and may therefore be a target for research into new treatments for pancreatic cancer, which is one of the deadliest forms of cancer. The work is published in the journal Cancer Research.

Scientists at the National Institutes of Health (NIH) have leveraged artificial intelligence to transform a device designed to see tissues in the back of the eye into one sharp enough to make out individual cells. The technique provides imaging resolution that rivals the most advanced devices available and is cheaper, faster, and doesn’t require specialized equipment or expertise. The strategy has implications for early detection of disease and for the monitoring of treatment response by making what was once invisible now visible.

Caltech professor of medical engineering Wei Gao and his colleagues are envisioning a smart bandage of the future—a “lab on skin” that could not only help patients and caregivers monitor the status of chronic wounds but also deliver treatment and speed up the healing process for those cuts, incisions, scrapes, and burns that are slow to heal on their own.

This advancement expands the capabilities of how researchers can study disease and build tissues for therapy, such as type 1 diabetes.

The technology, which achieves single-cell resolution, could help in continuous, noninvasive patient assessment to guide medical treatments.

Epiminder announced today that it received FDA de novo authorization for its implantable continuous electroencephalogram monitoring (iCEM) system.

NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.

SAN DIEGO, April 23, 2025 /PRNewswire/ — Biolabs International LLC proudly introduces PowderTracer™, a groundbreaking, rapid surface test, and its companion app, designed to swiftly detect seven dangerous drugs. This innovative tool is poised to revolutionize forensic drug detection in the field, providing accurate results in under five minutes. PowderTracer™ addresses the urgent need for rapid, reliable drug identification, particularly in the face of the escalating opioid crisis and the increasingly sophisticated methods used by drug traffickers.

A team of scientists has uncovered the mechanism of cellular uptake for large and polar drugs and devised a novel strategy to optimize the capacity of drug-delivery into these cells. The team was led by Hong-yu Li, Ph.D., professor of medicinal chemistry and chemical biology with the Department of Pharmacology and the Barshop Institute at the University of Texas Health Science Center at San Antonio (UT Health San Antonio), together with teams from Duke University (Duke) and the University of Arkansas for Medical Sciences (UAMS)